Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. develops antiviral therapeutics using a proprietary structure-based drug discovery platform. News for COCP centers on CDI-988, an oral direct-acting protease inhibitor for norovirus infection, including clinical-study updates, FDA Fast Track designation and scientific presentations on its 3CL protease mechanism.
Company updates also cover financial results, financing activity, NIH-supported influenza A/B polymerase research, and broader pipeline references to respiratory viruses and coronaviruses.
Cocrystal Pharma (Nasdaq: COCP) presented favorable Phase 1 results for its oral pan-viral inhibitor CDI-988 at the 2025 Military Health System Research Symposium. The study demonstrated that all doses (100 mg to 1200 mg) were well-tolerated, with lower treatment-emergent adverse events in CDI-988 subjects compared to placebo groups.
Key findings include: 28% adverse events in SAD cohorts (vs. 40% placebo) and 53% in MAD cohorts (vs. 92% placebo). No severe adverse events or significant ECG changes were reported. The company plans to initiate a Phase 1b challenge study with CDI-988 in norovirus-infected subjects later this year, addressing an unmet medical need as there are currently no approved treatments or vaccines for norovirus.
Cocrystal Pharma (Nasdaq: COCP) announced that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for oral presentation at the 9th International Calicivirus Conference in September 2025. The presentation will showcase Phase 1 study results of CDI-988, designed as a treatment for norovirus infections.
CDI-988 was developed using Cocrystal's proprietary structure-based platform technology as a broad-spectrum inhibitor targeting 3CL viral proteases. The company has completed a Phase 1 randomized, double-blind, placebo-controlled study evaluating safety, tolerability, and pharmacokinetics in healthy adults. The drug aims to address norovirus infections, which cause severe gastrointestinal illness with an estimated global societal cost of $60 billion annually.
Cocrystal Pharma (NASDAQ: COCP) has announced its participation in the Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference. The company's management will engage in a fireside chat on Thursday, June 5, 2025, at 12:00 p.m. Eastern time.
The event will feature a live Q&A session, and qualified investors can request one-on-one meetings with management through the conference platform. A video webcast of the presentation will be available within 48 hours on both the Cocrystal website and Channelchek, where it will remain accessible for 90 days.
Cocrystal Pharma (NASDAQ: COCP) announces significant progress with its norovirus oral antiviral candidate CDI-988, which has demonstrated potent activity against emerging GII.17 variants that have become the dominant strain in 2024-2025 U.S. and European outbreaks. The drug candidate shows broad-spectrum antiviral activity against both GII.4 and GII.17 strains.
CDI-988, a pan-viral protease inhibitor, has completed Phase 1 trials with favorable safety and tolerability results. The company plans to initiate a human challenge study in 2025 for both treatment and prevention of norovirus infection. The drug targets the highly conserved region of the GII.17 protease, representing a potential first-in-class oral antiviral treatment.
Notably, norovirus causes approximately 685 million cases and 50,000 child deaths annually worldwide, with an estimated societal cost of $60 billion. Currently, there are no approved antiviral treatments or vaccines available.
Cocrystal Pharma (Nasdaq: COCP) has announced its participation in the upcoming Life Science Innovation Northwest (LSINW) 2025 Conference. Sam Lee, President and co-CEO, will deliver a company overview presentation on Wednesday, April 23, 2025 at 3:00 p.m. Pacific time. The conference will take place at the Seattle Convention Center from April 23-24.
Cocrystal Pharma (COCP) reported financial results for 2024 and provided updates on its antiviral drug development programs. The company reported a net loss of $17.5 million ($1.72 per share) compared to $18.0 million in 2023. R&D expenses decreased to $12.5 million from $15.2 million, while G&A expenses reduced to $5.3 million from $6.0 million.
The company's cash position stood at $9.9 million as of December 31, 2024, down from $26.4 million year-over-year. Key developments include plans to initiate a norovirus human challenge study for CDI-988 and continuation of the influenza challenge study for CC-42344. The company's pipeline focuses on developing treatments for norovirus, influenza, and coronavirus using their proprietary structure-based drug discovery platform.
Cocrystal Pharma (Nasdaq: COCP) has announced its participation in the Zacks SCR Life Sciences Virtual Investor Forum scheduled for March 13, 2025. The company's management will engage in a fireside chat at 11:30 a.m. Eastern time (8:30 a.m. Pacific time), hosted by Zacks Small Cap Research Senior Analyst David Bautz, PhD.
Investors can pre-register for the virtual presentation through Cocrystal's website and will have the opportunity to:
- Submit questions during the live event
- Request one-on-one meetings with management via the 'Book A Meeting' button
- Access a replay of the event through the company's website